It’s not uncommon for drug developers put a positive spin on lacklustre clinical data, but CytoDyn’s attempts seems to have irritated the US regulator, specifically relating to its use of subgroup analyses to try to indicate a benefit for leronlimab.
The biotech has run two studies to try to repurpose HIV and cancer candidate leronlimab as a COVID-19 therapy, neither of which achieved their primary objectives, but has said it will nevertheless file the data with regulators in countries including India and the Philippines.
